Zacks Research Lifts Earnings Estimates for Teladoc Health

Teladoc Health, Inc. (NYSE:TDOC) – Stock analysts at Zacks Research lifted their FY2024 earnings per share estimates for shares of Teladoc Health in a research report issued on Wednesday, November 13th. Zacks Research analyst R. Department now forecasts that the health services provider will post earnings per share of ($1.15) for the year, up from their prior forecast of ($1.31). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The firm had revenue of $640.51 million during the quarter, compared to analysts’ expectations of $630.50 million.

Other research analysts have also issued reports about the company. Canaccord Genuity Group lowered their price objective on Teladoc Health from $25.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. DA Davidson lowered their price target on Teladoc Health from $12.00 to $8.00 and set a “neutral” rating for the company in a report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a report on Friday, November 1st. Piper Sandler lowered their target price on shares of Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Barclays lifted their price target on shares of Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Fourteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Teladoc Health has an average rating of “Hold” and an average target price of $12.08.

Teladoc Health Stock Down 1.3 %

Shares of NYSE TDOC opened at $8.93 on Monday. The company has a market capitalization of $1.54 billion, a P/E ratio of -1.55 and a beta of 0.90. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. The company has a 50 day simple moving average of $8.96 and a 200-day simple moving average of $9.31. Teladoc Health has a 1 year low of $6.76 and a 1 year high of $22.54.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Clearline Capital LP boosted its stake in shares of Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock worth $42,682,000 after buying an additional 3,483,665 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Teladoc Health by 195.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 95,307 shares of the health services provider’s stock valued at $932,000 after purchasing an additional 63,028 shares during the last quarter. Mackenzie Financial Corp increased its holdings in shares of Teladoc Health by 170.7% in the second quarter. Mackenzie Financial Corp now owns 107,255 shares of the health services provider’s stock valued at $1,049,000 after purchasing an additional 67,640 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of Teladoc Health by 188.7% during the first quarter. Janney Montgomery Scott LLC now owns 31,594 shares of the health services provider’s stock worth $477,000 after purchasing an additional 20,651 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in Teladoc Health by 221.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock valued at $51,865,000 after buying an additional 3,655,436 shares during the last quarter. 76.82% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Teladoc Health

In other news, CFO Mala Murthy sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the completion of the sale, the chief financial officer now owns 85,767 shares in the company, valued at approximately $614,091.72. The trade was a 9.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Willem Waters sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total value of $30,200.88. Following the transaction, the chief operating officer now directly owns 78,309 shares in the company, valued at approximately $560,692.44. The trade was a 5.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,051 shares of company stock valued at $143,565 over the last 90 days. 0.95% of the stock is owned by corporate insiders.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.